Fresenius Kabi Usa patents expiration
1. Acetaminophen patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8741959 | FRESENIUS KABI USA | Paracetamol for parenteral administration |
Apr, 2030
(5 years from now) | |
Drugs and Companies using ACETAMINOPHEN ingredient
Market Authorisation Date: 28 October, 2015
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS
ACETAMINOPHEN family patents
2. Bortezomib patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8962572 | FRESENIUS KABI USA | Bortezomib formulations |
Nov, 2032
(8 years from now) | |
Drugs and Companies using BORTEZOMIB ingredient
Market Authorisation Date: 06 November, 2017
Treatment: NA
Dosage: POWDER;INTRAVENOUS
BORTEZOMIB family patents
3. Caspofungin Acetate patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9636407 | FRESENIUS KABI USA | Caspofungin acetate formulations |
Dec, 2032
(8 years from now) | |
Drugs and Companies using CASPOFUNGIN ACETATE ingredient
Market Authorisation Date: 30 December, 2016
Treatment: NA
Dosage: POWDER;INTRAVENOUS
CASPOFUNGIN ACETATE family patents
4. Dilaudid patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6589960 | FRESENIUS KABI USA | Hydromorphone and hydrocodone compositions and methods for their synthesis |
Nov, 2020
(3 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9731082 | FRESENIUS KABI USA | Drug container |
Apr, 2032
(7 years from now) | |
| US9248229 | FRESENIUS KABI USA | Packaging system for oxygen-sensitive drugs |
Mar, 2034
(9 years from now) | |
Drugs and Companies using HYDROMORPHONE HYDROCHLORIDE ingredient
Market Authorisation Date: 16 January, 2020
Treatment: NA
Dosage: INJECTABLE;INJECTION
DILAUDID family patents
5. Dilaudid-hp patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6589960 | FRESENIUS KABI USA | Hydromorphone and hydrocodone compositions and methods for their synthesis |
Nov, 2020
(3 years ago) | |
| US9731082 | FRESENIUS KABI USA | Drug container |
Apr, 2032
(7 years from now) | |
| US9248229 | FRESENIUS KABI USA | Packaging system for oxygen-sensitive drugs |
Mar, 2034
(9 years from now) | |
Drugs and Companies using HYDROMORPHONE HYDROCHLORIDE ingredient
Market Authorisation Date: 16 January, 2020
Treatment: NA
Dosage: INJECTABLE;INJECTION
DILAUDID-HP family patents
6. Diprivan patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8476010 | FRESENIUS KABI USA | Propofol formulations with non-reactive container closures |
Dec, 2024
(7 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5908869 | FRESENIUS KABI USA | Propofol compositions containing edetate |
Mar, 2015
(9 years ago) | |
| US5714520 | FRESENIUS KABI USA | Propofol compostion containing edetate |
Mar, 2015
(9 years ago) | |
| US5731355 | FRESENIUS KABI USA | Pharmaceutical compositions of propofol and edetate |
Mar, 2015
(9 years ago) | |
| US5731356 | FRESENIUS KABI USA | Pharmaceutical compositions of propofol and edetate |
Mar, 2015
(9 years ago) | |
|
US5714520 (Pediatric) | FRESENIUS KABI USA | Propofol compostion containing edetate |
Sep, 2015
(8 years ago) | |
|
US5731356 (Pediatric) | FRESENIUS KABI USA | Pharmaceutical compositions of propofol and edetate |
Sep, 2015
(8 years ago) | |
|
US5908869 (Pediatric) | FRESENIUS KABI USA | Propofol compositions containing edetate |
Sep, 2015
(8 years ago) | |
|
US5731355 (Pediatric) | FRESENIUS KABI USA | Pharmaceutical compositions of propofol and edetate |
Sep, 2015
(8 years ago) | |
|
US8476010 (Pediatric) | FRESENIUS KABI USA | Propofol formulations with non-reactive container closures |
Jun, 2025
(1 year, 1 month from now) | |
Drugs and Companies using PROPOFOL ingredient
Market Authorisation Date: 02 October, 1989
Treatment: Method of improving the time for administration or the time between changes of giving sets for the drug product; Method of producing anesthesia; Method for limiting the potential for microbial growth ...
Dosage: INJECTABLE;INJECTION
DIPRIVAN family patents
7. Fulvestrant patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10188663 | FRESENIUS KABI USA | Fulvestrant formulations |
Feb, 2034
(9 years from now) | |
| US9833459 | FRESENIUS KABI USA | Fulvestrant formulations |
Feb, 2034
(9 years from now) | |
| US9271990 | FRESENIUS KABI USA | Fulvestrant formulations |
May, 2034
(10 years from now) | |
Drugs and Companies using FULVESTRANT ingredient
Market Authorisation Date: 20 May, 2019
Treatment: Treatment of hormone receptor positive advanced breast cancer in postmenopausal women
Dosage: SOLUTION;INTRAMUSCULAR
FULVESTRANT family patents
8. Levothyroxine Sodium patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9168238 | FRESENIUS KABI USA | Levothyroxine formulations |
Aug, 2032
(8 years from now) | |
| US9168239 | FRESENIUS KABI USA | Levothyroxine formulations |
Aug, 2032
(8 years from now) | |
| US9006289 | FRESENIUS KABI USA | Levothyroxine formulations |
Oct, 2032
(8 years from now) | |
| US9782376 | FRESENIUS KABI USA | Levothyroxine liquid formulations |
Dec, 2036
(12 years from now) | |
| US11135190 | FRESENIUS KABI USA | Levothyroxine liquid formulations |
Dec, 2036
(12 years from now) | |
| US10398669 | FRESENIUS KABI USA | Levothyroxine liquid formulations |
Dec, 2036
(12 years from now) | |
Drugs and Companies using LEVOTHYROXINE SODIUM ingredient
Market Authorisation Date: 24 June, 2011
Treatment: NA
Dosage: POWDER;INTRAVENOUS; SOLUTION;INTRAVENOUS
LEVOTHYROXINE SODIUM family patents
9. Morphine Sulfate patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9248229 | FRESENIUS KABI USA | Packaging system for oxygen-sensitive drugs |
Mar, 2034
(9 years from now) | |
| US9072781 | FRESENIUS KABI USA | Morphine formulations |
Mar, 2034
(9 years from now) | |
| US9192608 | FRESENIUS KABI USA | Morphine formulations |
Mar, 2034
(9 years from now) | |
Drugs and Companies using MORPHINE SULFATE ingredient
Market Authorisation Date: 30 October, 2013
Treatment: Treatment of pain
Dosage: SOLUTION;INTRAMUSCULAR, INTRAVENOUS
MORPHINE SULFATE family patents
10. Naropin patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5834489 | FRESENIUS KABI USA | Methods and compositions for the treatment of pain utilizing ropivacaine |
May, 2014
(9 years ago) | |
| US5670524 | FRESENIUS KABI USA | Methods and compositions for the treatment of pain utilizing ropivacaine |
Sep, 2014
(9 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8118802 | FRESENIUS KABI USA | Connector for packaging containing medical fluids and packaging for medical fluids |
May, 2023
(11 months ago) | |
| US8162915 | FRESENIUS KABI USA | Connector for packings containing medical liquids, and corresponding packing for medical liquids |
May, 2024
(25 days from now) | |
| US7828787 | FRESENIUS KABI USA | Connector for packaging containing medical fluids and packaging for medical fluids |
Oct, 2025
(1 year, 5 months from now) | |
| US7857802 | FRESENIUS KABI USA | Connector for medical liquid-containing packages and medical liquid-containing packages |
Nov, 2026
(2 years from now) | |
Drugs and Companies using ROPIVACAINE HYDROCHLORIDE ingredient
Market Authorisation Date: 04 January, 2011
Treatment: Method of treating pain using a pharmaceutically acceptable salt of ropivacaine and administering a composition containing less than 0.5% by weight of ropivacaine; Method of treating pain using a phar...
Dosage: SOLUTION;INJECTION
NAROPIN family patents
11. Omegaven patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10350186 | FRESENIUS KABI USA | Treatment and prevention of liver disease associated with parenteral nutrition (PN) |
Nov, 2024
(6 months from now) | |
| US9566260 | FRESENIUS KABI USA | Treatment and prevention of liver disease associated with parenteral nutrition (PN) |
Jul, 2025
(1 year, 2 months from now) | |
| US9629821 | FRESENIUS KABI USA | Treatment and prevention of liver disease associated with parenteral nutrition (PN) |
Jul, 2025
(1 year, 2 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-202) | Jul 27, 2025 |
| New Chemical Entity Exclusivity(NCE) | Jul 27, 2023 |
Drugs and Companies using FISH OIL TRIGLYCERIDES ingredient
NCE-1 date: 27 July, 2022
Market Authorisation Date: 27 July, 2018
Treatment: Treatment of parenteral nutrition-associated cholestasis in patients under the age of 12; Treatment of liver disease through nutrition for patients under the age of 12; Use for patients with parentera...
Dosage: EMULSION;INTRAVENOUS
OMEGAVEN family patents